FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 355:704-712 August 17, 2006 Number 7 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text PowerPoint Slide Set Purchase this article Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

This Journal feature begins with a case vignette that includes a therapeutic recommendation. A discussion of the clinical problem and the mechanism of benefit of this form of therapy follows. Major clinical studies, the clinical use of this therapy, and potential adverse effects are reviewed. Relevant formal guidelines, if they exist, are presented. The article ends with the authors' clinical recommendations.

Rheumatoid arthritis developed in a 25-year-old woman, who was found to have a positive rheumatoid factor (150 IU per milliliter); she had no periarticular radiologic erosions or extraarticular disease. Oral methotrexate was started and incrementally increased to 20 mg . . . [Full Text of this Article]

The Clinical Problem

Pathophysiology and Effect of Therapy

Clinical Evidence

Clinical Use

Adverse Effects

Areas of Uncertainty

Guidelines

Recommendations

Source Information

From the Department of Rheumatology, Kings College London School of Medicine, Weston Education Centre, Kings College (D.L.S., G.H.K.); the Department of Rheumatology, Kings College Hospital (D.L.S.); and the Department of Rheumatology, University Hospital Lewisham (G.H.K.) — all in London.

Related Letters:

Tumor Necrosis Factor Inhibitors for Rheumatoid Arthritis
Roos J. C., Ostor A. J., Okamoto H., Dentener M. A., Wouters E. F.M., Scott D.L., Kingsley G.H.
Extract | Full Text | PDF  
N Engl J Med 2006; 355:2046-2048, Nov 9, 2006. Correspondence

This article has been cited by other articles:

• Summers, G. D., Deighton, C. M., Rennie, M. J., Booth, A. H. (2008). Rheumatoid cachexia: a clinical perspective. Rheumatology (Oxford) 47: 1124-1131 [Abstract] [Full Text]  
• Pedras-Vasconcelos, J. A., Puig, M., Sauder, C., Wolbert, C., Ovanesov, M., Goucher, D., Verthelyi, D. (2008). Immunotherapy with CpG Oligonucleotides and Antibodies to TNF-{alpha} Rescues Neonatal Mice from Lethal Arenavirus-Induced Meningoencephalitis. J. Immunol. 180: 8231-8240 [Abstract] [Full Text]  
• Choy, E H S, Smith, C M, Farewell, V, Walker, D, Hassell, A, Chau, L, Scott, D L, for the CARDERA (Combination Anti-Rheumatic Drugs, (2008). Factorial randomised controlled trial of glucocorticoids and combination disease modifying drugs in early rheumatoid arthritis. Ann Rheum Dis 67: 656-663 [Abstract] [Full Text]  
• Yamashita, M., Otsuka, F., Mukai, T., Otani, H., Inagaki, K., Miyoshi, T., Goto, J., Yamamura, M., Makino, H. (2008). Simvastatin antagonizes tumor necrosis factor-{alpha} inhibition of bone morphogenetic proteins-2-induced osteoblast differentiation by regulating Smad signaling and Ras/Rho-mitogen-activated protein kinase pathway. J Endocrinol 196: 601-613 [Abstract] [Full Text]  
• Dower, K., Ellis, D. K., Saraf, K., Jelinsky, S. A., Lin, L.-L. (2008). Innate Immune Responses to TREM-1 Activation: Overlap, Divergence, and Positive and Negative Cross-Talk with Bacterial Lipopolysaccharide. J. Immunol. 180: 3520-3534 [Abstract] [Full Text]  
• Kanamaru, Y., Pfirsch, S., Aloulou, M., Vrtovsnik, F., Essig, M., Loirat, C., Deschenes, G., Guerin-Marchand, C., Blank, U., Monteiro, R. C. (2008). Inhibitory ITAM Signaling by Fc{alpha}RI-FcR{gamma} Chain Controls Multiple Activating Responses and Prevents Renal Inflammation. J. Immunol. 180: 2669-2678 [Abstract] [Full Text]  
• Zaba, L. C., Cardinale, I., Gilleaudeau, P., Sullivan-Whalen, M., Suarez-Farinas, M., Fuentes-Duculan, J., Novitskaya, I., Khatcherian, A., Bluth, M. J., Lowes, M. A., Krueger, J. G. (2007). Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responses. JEM 204: 3183-3194 [Abstract] [Full Text]  
• Araujo, E. P., De Souza, C. T., Ueno, M., Cintra, D. E., Bertolo, M. B., Carvalheira, J. B., Saad, M. J., Velloso, L. A. (2007). Infliximab Restores Glucose Homeostasis in an Animal Model of Diet-Induced Obesity and Diabetes. Endocrinology 148: 5991-5997 [Abstract] [Full Text]  
• Song, H., Qiao, F., Atkinson, C., Holers, V. M., Tomlinson, S. (2007). A Complement C3 Inhibitor Specifically Targeted to Sites of Complement Activation Effectively Ameliorates Collagen-Induced Arthritis in DBA/1J Mice. J. Immunol. 179: 7860-7867 [Abstract] [Full Text]  
• Barbuio, R., Milanski, M., Bertolo, M. B, Saad, M. J, Velloso, L. A (2007). Infliximab reverses steatosis and improves insulin signal transduction in liver of rats fed a high-fat diet. J Endocrinol 194: 539-550 [Abstract] [Full Text]  
• Wieser, F., Cohen, M., Gaeddert, A., Yu, J., Burks-Wicks, C., Berga, S. L., Taylor, R. N. (2007). Evolution of medical treatment for endometriosis: back to the roots?. Hum Reprod Update 13: 487-499 [Abstract] [Full Text]  
• Ma, Y., HayGlass, K. T., Becker, A. B., Fan, Y., Yang, X., Basu, S., Srinivasan, G., Simons, F. E. R., Halayko, A. J., Peng, Z. (2007). Novel Recombinant Interleukin-13 Peptide-based Vaccine Reduces Airway Allergic Inflammatory Responses in Mice. Am. J. Respir. Crit. Care Med. 176: 439-445 [Abstract] [Full Text]  
• Kitamura, M., Iwabuchi, K., Kitaichi, N., Kon, S., Kitamei, H., Namba, K., Yoshida, K., Denhardt, D. T., Rittling, S. R., Ohno, S., Uede, T., Onoe, K. (2007). Osteopontin Aggravates Experimental Autoimmune Uveoretinitis in Mice. J. Immunol. 178: 6567-6572 [Abstract] [Full Text]  
• Juhn, P., Phillips, A., Buto, K. (2007). Balancing Modern Medical Benefits And Risks. Health Aff (Millwood) 26: 647-652 [Abstract] [Full Text]  
• Pizarro, T. T., Cominelli, F. (2007). Cloning IL-1 and the Birth of a New Era in Cytokine Biology. J. Immunol. 178: 5411-5412 [Full Text]  
• Gonzalez-Rey, E., Chorny, A., Del Moral, R. G, Varela, N., Delgado, M. (2007). Therapeutic effect of cortistatin on experimental arthritis by downregulating inflammatory and Th1 responses. Ann Rheum Dis 66: 582-588 [Abstract] [Full Text]  
• Watson, A. J M (2007). In vivo single-photon emission computed tomography imaging of apoptosis in Crohn's disease and anti-tumour necrosis factor therapy. Gut 56: 461-463 [Full Text]  
• Dorner, T., Burmester, G. R. (2007). No B cells--no active RA? Advances in B cell depletion in RA--repeated therapy under conditions of clinical practice. Rheumatology (Oxford) 46: 563-564 [Full Text]  
• Roos, J. C., Ostor, A. J., Okamoto, H., Dentener, M. A., Wouters, E. F.M., Scott, D.L., Kingsley, G.H. (2006). Tumor Necrosis Factor Inhibitors for Rheumatoid Arthritis. NEJM 355: 2046-2048 [Full Text]